Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | Cellular kinetics of CAR-T & prophylactic promise

Carl June • 20 Jun 2019
ICML 2019
Lymphoma Non-Hodgkin Lymphoma CAR-T

Carl June, MD, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, discusses the expansion and durability of CAR T-cells following treatment, as well as speculating upon their future potential to even be given prior to disease in those at high risk. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

More from Carl June

3:24
Next-generation CAR T-cells for lymphoma and beyond
Carl June • 20 Jun 2019

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals